Similarly, Skp2 is increased in paclitaxel-resistant prostate cancer cells68 and the proteasome inhibitor bortezomib, carfilzomib or ixazomib-resistant multiple myeloma cells69. This evidence concerns the gene SKP2 and Familial prostate cancer.